Feng N, Burns J W, Bracy L, Greenberg H B
Department of Medicine, Microbiology and Immunology, Stanford University School of Medicine, California 94305.
J Virol. 1994 Dec;68(12):7766-73. doi: 10.1128/JVI.68.12.7766-7773.1994.
Rotaviruses are the single most important cause of severe diarrhea in young children worldwide, and vaccination is probably the most effective way to control the disease. Most current live virus vaccine candidates are based on the host range-restricted attenuation of heterologous animal rotaviruses in humans. The protective efficacy of these vaccine candidates has been variable. To better understand the nature of the heterologous rotavirus-induced active immune response, we compared the differences in the mucosal and systemic immune responses generated by heterologous (nonmurine) and homologous (murine) rotaviruses as well as the ability of these infections to produce subsequent protective immunity in a mouse model. Sucking mice were orally inoculated with a heterologous simian or bovine rotavirus (strain RRV or NCDV) or a homologous murine rotavirus (wild-type or tissue culture-adapted) strain EHP at various doses. Six weeks later, mice were challenged with a virulent murine rotavirus (wild-type strain ECW) and the shedding of viral antigen in feces was quantitated. Levels of rotavirus-specific serum immunoglobulin G (IgG) and fecal IgA prior to challenge were measured and correlated with subsequent viral shedding or protection. Heterologous rotavirus-induced active protection was highly dependent on the strain and dose of the virus tested. Mice inoculated with a high dose (10(7) PFU per mouse) of RRV were completely protected, while the protection was diminished in animals inoculated with NCDV or lower doses of RRV. The ability of a heterologous rotavirus to stimulate a detectable intestinal IgA response correlated with the ability of the virus to generate protective immunity. Serum IgG titer did not correlate with protection. Homologous rotavirus infection, on the other hand, was much more efficient at inducing both mucosal and systemic immune responses as well as protection regardless of the virulence of the virus strain or the size of the immunizing dose.
轮状病毒是全球幼儿严重腹泻的最重要单一病因,而接种疫苗可能是控制该疾病的最有效方法。目前大多数活病毒候选疫苗是基于异源动物轮状病毒在人体内宿主范围受限的减毒。这些候选疫苗的保护效力各不相同。为了更好地了解异源轮状病毒诱导的主动免疫反应的本质,我们比较了异源(非鼠源)和同源(鼠源)轮状病毒产生的黏膜和全身免疫反应的差异,以及这些感染在小鼠模型中产生后续保护性免疫的能力。给吮乳小鼠口服接种不同剂量的异源猿猴或牛轮状病毒(RRV株或NCDV株)或同源鼠轮状病毒(野生型或组织培养适应型)EHP株。六周后,用强毒力鼠轮状病毒(野生型ECW株)攻击小鼠,并对粪便中病毒抗原的排出量进行定量。检测攻击前轮状病毒特异性血清免疫球蛋白G(IgG)和粪便IgA的水平,并将其与后续病毒排出或保护情况相关联。异源轮状病毒诱导的主动保护高度依赖于所测试病毒的毒株和剂量。接种高剂量(每只小鼠10(7) PFU)RRV的小鼠得到完全保护,而接种NCDV或较低剂量RRV的动物保护作用减弱。异源轮状病毒刺激可检测到的肠道IgA反应的能力与该病毒产生保护性免疫的能力相关。血清IgG滴度与保护作用无关。另一方面,同源轮状病毒感染在诱导黏膜和全身免疫反应以及保护方面效率更高,无论病毒毒株的毒力或免疫剂量大小如何。